IP Library › Granted Patent US 11,608,510
Granted Patent B2
US 11,608,510 · App. 16/370,735 · Granted Mar 21, 2023

Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism

Inventors: Katja Pekrun (Palo Alto, CA); Mark A. Kay (Los Altos, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C12N15/86A61K47/6901C07K14/015C07K14/075C12N15/102C12N7/00C12N15/902C12N2710/10041C12N2710/10071C12N2710/10134C12N2710/10141C12N2750/14123
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,608,510
App. No.
16/370,735
Granted
Mar 21, 2023
Kind
B2
Abstract

The present invention relates to variant AAV capsid polypeptides, wherein the variant AAV capsid polypeptides exhibit increased transduction and/or tropism in human pancreatic tissue or human islets as compared non-variant parent capsid polypeptides.

Claims (26)

1. An adeno-associated virus (AAV) capsid polypeptide, wherein said AAV capsid polypeptide sequence is selected from the group consisting of AAV-10A1 (SEQ ID NO:1), AAV-10A3 (SEQ ID NO:2), AAV-10A4 (SEQ ID NO:3), AAV-10A5 (SEQ ID NO:4), AAV-18A1 (SEQ ID NO:5), AAV-10B1 (SEQ ID NO:6), AAV-10B3 (SEQ ID NO:7), AAV-10B5 (SEQ ID NO:8), AAV-10B6 (SEQ ID NO:9), AAV-10B7 (SEQ ID NO:10), AAV-18B2 (SEQ ID NO:12), and AAV-18B3 (SEQ ID NO:13).

2. An adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding an AAV capsid polypeptide, wherein said AAV capsid polypeptide sequence is selected from the group consisting of AAV-10A1 (SEQ ID NO:1), AAV-10A3 (SEQ ID NO:2), AAV-10A4 (SEQ ID NO:3), AAV-10A5 (SEQ ID NO:4), AAV-18A1 (SEQ ID NO:5), AAV-10B1 (SEQ ID NO:6), AAV-10B3 (SEQ ID NO:7), AAV-10B5 (SEQ ID NO:8), AAV-10B6 (SEQ ID NO:9), AAV-10B7 (SEQ ID NO:10), AAV-18B2 (SEQ ID NO:12), and AAV-18B3 (SEQ ID NO:13).

3. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-10A1 (SEQ ID NO:1).

4. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-10A3 (SEQ ID NO:2).

5. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-10A4 (SEQ ID NO:3).

6. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-10A5 (SEQ ID NO:4).

7. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-18A1 (SEQ ID NO:5).

8. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-10B1 (SEQ ID NO:6).

9. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-10B3 (SEQ ID NO:7).

10. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-10B5 (SEQ ID NO:8).

11. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-10B6 (SEQ ID NO:9).

12. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-10B7 (SEQ ID NO:10).

13. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-18B2 (SEQ ID NO:12).

14. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide sequence comprises AAV-18B3 (SEQ ID NO:13).

15. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-10A1 (SEQ ID NO:1).

16. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-10A3 (SEQ ID NO:2).

17. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-10A4 (SEQ ID NO:3).

18. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-10A5 (SEQ ID NO:4).

19. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-18A1 (SEQ ID NO:5).

20. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-10B1 (SEQ ID NO:6).

21. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-10B3 (SEQ ID NO:7).

22. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-10B5 (SEQ ID NO:8).

23. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-10B6 (SEQ ID NO:9).

24. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-10B7 (SEQ ID NO:10).

25. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-18B2 (SEQ ID NO:12).

26. The AAV vector of claim 2 , wherein the AAV capsid polypeptide sequence comprises AAV-18B3 (SEQ ID NO:13).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2019
From: PEKRUN, KATJA; KAY, MARK A.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 049445/0885 →
Continuity (3)
Provisional Application 62651010 · Mar 30, 2018
Provisional Application 62745226 · Oct 12, 2018
Related Publication 20200024616A1 · Jan 23, 2020
Cited By (1)
US 12,467,065